Bridgewater Associates LP Sells 93,492 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Bridgewater Associates LP decreased its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 61.2% in the third quarter, Holdings Channel.com reports. The fund owned 59,254 shares of the company’s stock after selling 93,492 shares during the period. Bridgewater Associates LP’s holdings in Henry Schein were worth $4,320,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its holdings in shares of Henry Schein by 5.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 184,482 shares of the company’s stock valued at $13,449,000 after purchasing an additional 9,465 shares during the last quarter. Quantbot Technologies LP lifted its position in shares of Henry Schein by 342.0% in the third quarter. Quantbot Technologies LP now owns 54,822 shares of the company’s stock worth $3,997,000 after buying an additional 42,419 shares in the last quarter. FMR LLC boosted its stake in Henry Schein by 7.8% during the third quarter. FMR LLC now owns 3,280,890 shares of the company’s stock valued at $239,177,000 after buying an additional 237,888 shares during the last quarter. Dai ichi Life Insurance Company Ltd purchased a new position in Henry Schein during the 3rd quarter valued at approximately $396,000. Finally, The Manufacturers Life Insurance Company increased its stake in Henry Schein by 8.1% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 540,089 shares of the company’s stock worth $39,372,000 after acquiring an additional 40,625 shares during the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Henry Schein

In related news, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the sale, the senior vice president now directly owns 71,833 shares in the company, valued at $4,978,026.90. The trade was a 22.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Michael S. Ettinger sold 12,240 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the completion of the sale, the chief operating officer now directly owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. This trade represents a 12.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by company insiders.

Henry Schein Trading Down 0.8 %

HSIC opened at $77.05 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The stock’s 50 day moving average price is $71.36 and its 200-day moving average price is $69.89. Henry Schein, Inc. has a one year low of $63.67 and a one year high of $82.63. The stock has a market cap of $9.61 billion, a price-to-earnings ratio of 31.71, a P/E/G ratio of 2.23 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.17 by $0.05. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.24 billion. During the same quarter in the prior year, the company posted $1.32 EPS. Henry Schein’s quarterly revenue was up .4% on a year-over-year basis. On average, equities analysts forecast that Henry Schein, Inc. will post 4.78 EPS for the current year.

Wall Street Analysts Forecast Growth

HSIC has been the subject of a number of research reports. JPMorgan Chase & Co. lowered their target price on Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. UBS Group dropped their price objective on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Evercore ISI upped their target price on shares of Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research report on Tuesday, October 8th. Robert W. Baird dropped their price target on Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Finally, StockNews.com upgraded Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. Six research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $79.38.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.